American Century Companies Inc. Increases Position in SI-BONE, Inc. (NASDAQ:SIBN)

American Century Companies Inc. grew its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 11.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,378,068 shares of the company’s stock after purchasing an additional 236,167 shares during the period. American Century Companies Inc. owned approximately 0.06% of SI-BONE worth $33,341,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Jane Street Group LLC increased its position in SI-BONE by 29.0% during the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after buying an additional 17,410 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after acquiring an additional 1,745 shares in the last quarter. State Street Corp raised its position in shares of SI-BONE by 5.1% in the 3rd quarter. State Street Corp now owns 1,081,871 shares of the company’s stock worth $15,125,000 after purchasing an additional 52,972 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock worth $11,791,000 after purchasing an additional 220,555 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in SI-BONE by 14.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock valued at $2,486,000 after purchasing an additional 22,732 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Insider Buying and Selling

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. The trade was a 1.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at $2,633,427.29. The trade was a 2.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,311 shares of company stock valued at $130,356 over the last 90 days. Company insiders own 3.90% of the company’s stock.

SI-BONE Stock Performance

Shares of SIBN stock opened at $14.04 on Friday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average price of $16.41 and a 200-day moving average price of $14.78. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $19.16. The firm has a market capitalization of $596.04 million, a PE ratio of -15.26 and a beta of 1.17.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, equities research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SIBN has been the subject of several recent analyst reports. Needham & Company LLC lifted their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Truist Financial reaffirmed a “buy” rating and issued a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE has an average rating of “Buy” and an average price target of $24.40.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.